메뉴 건너뛰기




Volumn 1, Issue 4, 2016, Pages

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: A single institution, real-life experience at the Medical University of Vienna

Author keywords

clinical benefit; ESMO MCBS; metastatic disease; quality control

Indexed keywords


EID: 85015742688     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2016-000066     Document Type: Article
Times cited : (18)

References (91)
  • 1
    • 84932627972 scopus 로고    scopus 로고
    • The 2015 oncology drug pipeline: Innovation drives the race to cure cancer
    • Buffery D. The 2015 oncology drug pipeline: innovation drives the race to cure cancer. Am Health Drug Benefits 2015;8:216-22.
    • (2015) Am Health Drug Benefits , vol.8 , pp. 216-222
    • Buffery, D.1
  • 3
    • 79957492218 scopus 로고    scopus 로고
    • Bending the cost curve in cancer care
    • Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-5.
    • (2011) N Engl J Med , vol.364 , pp. 2060-2065
    • Smith, T.J.1    Hillner, B.E.2
  • 4
    • 84886719809 scopus 로고    scopus 로고
    • Cancer drugs in the United States: Justum Pretium-the just price
    • Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 2013;31:3600-4.
    • (2013) J Clin Oncol , vol.31 , pp. 3600-3604
    • Kantarjian, H.M.1    Fojo, T.2    Mathisen, M.3
  • 5
    • 84903946015 scopus 로고    scopus 로고
    • Cost-effectiveness analyses of targeted oral anti-cancer drugs: A systematic review
    • Smieliauskas F, Chien CR, Shen C, et al. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics 2014;32:651-80.
    • (2014) Pharmacoeconomics , vol.32 , pp. 651-680
    • Smieliauskas, F.1    Chien, C.R.2    Shen, C.3
  • 6
    • 84939251874 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options
    • Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-77.
    • (2015) J Clin Oncol , vol.33 , pp. 2563-2577
    • Schnipper, L.E.1    Davidson, N.E.2    Wollins, D.S.3
  • 7
    • 85052680013 scopus 로고    scopus 로고
    • http://app.drugabacus.org/abacus-mskcc
  • 8
    • 84940648261 scopus 로고    scopus 로고
    • A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
    • Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-73.
    • (2015) Ann Oncol , vol.26 , pp. 1547-1573
    • Cherny, N.I.1    Sullivan, R.2    Dafni, U.3
  • 9
    • 85052698616 scopus 로고    scopus 로고
    • http://www.esmo.org/Policy/Magnitude-of-Clinical-Benefit-Scale/ Scale-Evaluation-Forms
  • 10
    • 84876970810 scopus 로고    scopus 로고
    • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    • Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71.
    • (2013) Lancet Oncol , vol.14 , pp. 461-471
    • Swain, S.M.1    Kim, S.B.2    Cortés, J.3
  • 11
    • 84923052492 scopus 로고    scopus 로고
    • Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
    • Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34.
    • (2015) N Engl J Med , vol.372 , pp. 724-734
    • Swain, S.M.1    Baselga, J.2    Kim, S.B.3
  • 12
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
    • (2012) N Engl J Med , vol.367 , pp. 1783-1791
    • Verma, S.1    Miles, D.2    Gianni, L.3
  • 13
    • 84896704753 scopus 로고    scopus 로고
    • Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer
    • Weslau M, Diéras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014;120:642-51.
    • (2014) Cancer , vol.120 , pp. 642-651
    • Weslau, M.1    Diéras, V.2    Sohn, J.H.3
  • 14
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 15
    • 77949884661 scopus 로고    scopus 로고
    • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    • Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
    • (2010) J Clin Oncol , vol.28 , pp. 1124-1130
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3
  • 16
    • 84864066561 scopus 로고    scopus 로고
    • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study
    • Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012;30:2585-92.
    • (2012) J Clin Oncol , vol.30 , pp. 2585-2592
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3
  • 17
    • 80053362290 scopus 로고    scopus 로고
    • Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
    • Von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011;47:2273-81.
    • (2011) Eur J Cancer , vol.47 , pp. 2273-2281
    • Von Minckwitz, G.1    Schwedler, K.2    Schmidt, M.3
  • 18
    • 84863078767 scopus 로고    scopus 로고
    • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    • Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
    • (2012) N Engl J Med , vol.366 , pp. 520-529
    • Baselga, J.1    Campone, M.2    Piccart, M.3
  • 19
    • 84922369296 scopus 로고    scopus 로고
    • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study
    • Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
    • (2015) Lancet Oncol , vol.16 , pp. 25-35
    • Finn, R.S.1    Crown, J.P.2    Lang, I.3
  • 20
    • 84937042338 scopus 로고    scopus 로고
    • Palbociclib in hormone-receptor-positive advanced breast cancer
    • Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19.
    • (2015) N Engl J Med , vol.373 , pp. 209-219
    • Turner, N.C.1    Ro, J.2    André, F.3
  • 21
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
    • (2007) N Engl J Med , vol.357 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 22
    • 11144357506 scopus 로고    scopus 로고
    • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    • O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
    • (2004) Ann Oncol , vol.15 , pp. 440-449
    • O'Brien, M.E.1    Wigler, N.2    Inbar, M.3
  • 23
    • 79953874259 scopus 로고    scopus 로고
    • RIBBON-1 Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    • Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1 Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
    • (2011) J Clin Oncol , vol.29 , pp. 1252-1260
    • Robert, N.J.1    Diéras, V.2    Glaspy, J.3
  • 24
    • 77954700380 scopus 로고    scopus 로고
    • Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    • Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
    • (2010) J Clin Oncol , vol.28 , pp. 3239-3247
    • Miles, D.W.1    Chan, A.2    Dirix, L.Y.3
  • 25
    • 32944482677 scopus 로고    scopus 로고
    • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer
    • Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
    • (2005) J Clin Oncol , vol.23 , pp. 7794-7803
    • Gradishar, W.J.1    Tjulandin, S.2    Davidson, N.3
  • 26
    • 79952487463 scopus 로고    scopus 로고
    • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
    • Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
    • (2011) Lancet , vol.377 , pp. 914-923
    • Cortes, J.1    O'Shaughnessy, J.2    Loesch, D.3
  • 27
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 28
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 29
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 30
    • 79960702788 scopus 로고    scopus 로고
    • Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
    • Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
    • (2011) J Clin Oncol , vol.29 , pp. 2866-2874
    • Fukuoka, M.1    Wu, Y.L.2    Thongprasert, S.3
  • 31
    • 84884736973 scopus 로고    scopus 로고
    • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    • Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
    • (2013) J Clin Oncol , vol.31 , pp. 3327-3334
    • Sequist, L.V.1    Yang, J.C.2    Yamamoto, N.3
  • 32
    • 84884605223 scopus 로고    scopus 로고
    • Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
    • Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3342-50.
    • (2013) J Clin Oncol , vol.31 , pp. 3342-3350
    • Yang, J.C.1    Hirsh, V.2    Schuler, M.3
  • 33
    • 84921892043 scopus 로고    scopus 로고
    • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
    • Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51.
    • (2015) Lancet Oncol , vol.16 , pp. 141-151
    • Yang, J.C.1    Wu, Y.L.2    Schuler, M.3
  • 34
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
    • (2013) N Engl J Med , vol.368 , pp. 2385-2394
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3
  • 35
    • 84918804764 scopus 로고    scopus 로고
    • First-line crizotinib versus chemotherapy in ALK-positive lung cancer
    • Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
    • (2014) N Engl J Med , vol.371 , pp. 2167-2177
    • Solomon, B.J.1    Mok, T.2    Kim, D.W.3
  • 36
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotiti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51.
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotiti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 37
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 2006;355:2542-50.
    • (2006) New Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 38
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
    • (2009) J Clin Oncol , vol.27 , pp. 1227-1234
    • Reck, M.1    Von Pawel, J.2    Zatloukal, P.3
  • 39
    • 77955877759 scopus 로고    scopus 로고
    • Early palliative care for patients with metastatic non-small-cell lung cancer
    • Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.
    • (2010) N Engl J Med , vol.363 , pp. 733-742
    • Temel, J.S.1    Greer, J.A.2    Muzikansky, A.3
  • 40
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
    • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 41
    • 77953541527 scopus 로고    scopus 로고
    • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
    • Capuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
    • (2010) Lancet Oncol , vol.11 , pp. 521-529
    • Capuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 42
    • 84892967581 scopus 로고    scopus 로고
    • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial
    • Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55.
    • (2014) Lancet Oncol , vol.15 , pp. 143-155
    • Reck, M.1    Kaiser, R.2    Mellemgaard, A.3
  • 43
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
    • (2015) N Engl J Med , vol.373 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3
  • 44
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
    • (2015) N Engl J Med , vol.373 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3
  • 45
    • 84925324704 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
    • Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692-700.
    • (2015) J Clin Oncol , vol.33 , pp. 692-700
    • Van Cutsem, E.1    Lenz, H.J.2    Köhne, C.H.3
  • 46
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
    • (2013) N Engl J Med , vol.369 , pp. 1023-1034
    • Douillard, J.Y.1    Oliner, K.S.2    Siena, S.3
  • 47
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 48
    • 84908139591 scopus 로고    scopus 로고
    • Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
    • Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014;371:1609-18.
    • (2014) N Engl J Med , vol.371 , pp. 1609-1618
    • Loupakis, F.1    Cremolini, C.2    Masi, G.3
  • 49
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19.
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Díaz-Rubio, E.3
  • 50
    • 84907027361 scopus 로고    scopus 로고
    • CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/ 5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO 2014
    • abstract LBA3
    • Venook AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/ 5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). ASCO 2014. J Clin Oncol 2014;32:abstract LBA3.
    • (2014) J Clin Oncol , vol.32
    • Venook, A.P.1    Niedzwiecki, D.2    Lenz, H.J.3
  • 51
    • 84908573757 scopus 로고    scopus 로고
    • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
    • Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75.
    • (2014) Lancet Oncol , vol.15 , pp. 1065-1075
    • Heinemann, V.1    Von Weikersthal, L.F.2    Decker, T.3
  • 52
    • 84884700039 scopus 로고    scopus 로고
    • AVEX Study Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial
    • Cunningham D, Lang I, Marcuello E, et al. AVEX Study Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1077-85.
    • (2013) Lancet Oncol , vol.14 , pp. 1077-1085
    • Cunningham, D.1    Lang, I.2    Marcuello, E.3
  • 53
    • 84929514070 scopus 로고    scopus 로고
    • Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
    • Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:1843-52.
    • (2015) Lancet , vol.385 , pp. 1843-1852
    • Simkens, L.H.1    Van Tinteren, H.2    May, A.3
  • 54
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 55
    • 84871720057 scopus 로고    scopus 로고
    • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial
    • Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
    • (2013) Lancet Oncol , vol.14 , pp. 29-37
    • Bennouna, J.1    Sastre, J.2    Arnold, D.3
  • 56
    • 84867047384 scopus 로고    scopus 로고
    • Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    • Van Cutsem E, Tabernero J, Lakorny R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-06.
    • (2012) J Clin Oncol , vol.30 , pp. 3499-3506
    • Van Cutsem, E.1    Tabernero, J.2    Lakorny, R.3
  • 57
    • 78149239651 scopus 로고    scopus 로고
    • Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    • Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
    • (2010) J Clin Oncol , vol.28 , pp. 4706-4713
    • Peeters, M.1    Price, T.J.2    Cervantes, A.3
  • 58
    • 84899940235 scopus 로고    scopus 로고
    • Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer
    • Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107-16.
    • (2014) Ann Oncol , vol.25 , pp. 107-116
    • Peeters, M.1    Price, T.J.2    Cervantes, A.3
  • 59
    • 84933673498 scopus 로고    scopus 로고
    • Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
    • Taberno J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508.
    • (2015) Lancet Oncol , vol.16 , pp. 499-508
    • Taberno, J.1    Yoshino, T.2    Cohn, A.L.3
  • 60
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 61
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 62
    • 84929310633 scopus 로고    scopus 로고
    • Randomized trial of TAS-102 for refractory metastatic colorectal cancer
    • Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372:1909-19.
    • (2015) N Engl J Med , vol.372 , pp. 1909-1919
    • Mayer, R.J.1    Van Cutsem, E.2    Falcone, A.3
  • 63
    • 84872921660 scopus 로고    scopus 로고
    • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial
    • Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
    • (2013) Lancet , vol.381 , pp. 303-312
    • Grothey, A.1    Van Cutsem, E.2    Sobrero, A.3
  • 64
    • 84911864613 scopus 로고    scopus 로고
    • Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup
    • (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study
    • Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520-6.
    • (2014) J Clin Oncol , vol.32 , pp. 3520-3526
    • Guimbaud, R.1    Louvet, C.2    Ries, P.3
  • 65
    • 84948456752 scopus 로고    scopus 로고
    • Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: A study of the US gastric cancer consortium
    • Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 2015;33:3874-9.
    • (2015) J Clin Oncol , vol.33 , pp. 3874-3879
    • Shah, M.A.1    Janjigian, Y.Y.2    Stoller, R.3
  • 66
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    • Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3
  • 67
    • 38049047178 scopus 로고    scopus 로고
    • Capecitabine and oxaliplatin for advanced esophagogastric cancer
    • Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
    • (2008) N Engl J Med , vol.358 , pp. 36-46
    • Cunningham, D.1    Starling, N.2    Rao, S.3
  • 68
    • 84892852372 scopus 로고    scopus 로고
    • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial
    • Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9.
    • (2014) Lancet , vol.383 , pp. 31-39
    • Fuchs, C.S.1    Tomasek, J.2    Yong, C.J.3
  • 69
    • 84908139963 scopus 로고    scopus 로고
    • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial
    • Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-35.
    • (2014) Lancet Oncol , vol.15 , pp. 1224-1235
    • Wilke, H.1    Muro, K.2    Van Cutsem, E.3
  • 70
    • 84862981823 scopus 로고    scopus 로고
    • Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone
    • Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-18.
    • (2012) J Clin Oncol , vol.30 , pp. 1513-1518
    • Kang, J.H.1    Lee, S.I.2    Lim Do, H.3
  • 71
    • 84939864061 scopus 로고    scopus 로고
    • Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
    • Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-46.
    • (2015) N Engl J Med , vol.373 , pp. 737-746
    • Sweeney, C.J.1    Chen, Y.H.2    Carducci, M.3
  • 72
    • 84961215473 scopus 로고    scopus 로고
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    • James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77.
    • (2016) Lancet , vol.387 , pp. 1163-1177
    • James, N.D.1    Sydes, M.R.2    Clarke, N.W.3
  • 73
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
    • (2004) N Engl J Med , vol.351 , pp. 1502-1512
    • Tannock, I.F.1    De Wit, R.2    Berry, W.R.3
  • 74
    • 84904871070 scopus 로고    scopus 로고
    • Enzalutamide in metastatic prostate cancer before chemotherapy
    • Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33.
    • (2014) N Engl J Med , vol.371 , pp. 424-433
    • Beer, T.M.1    Armstrong, A.J.2    Rathkopf, D.E.3
  • 75
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
    • (2013) N Engl J Med , vol.369 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 76
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 77
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
    • (2012) N Engl J Med , vol.367 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 78
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
    • De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 79
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 80
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 81
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
    • (2009) J Clin Oncol , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 82
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
    • Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
    • (2007) Lancet , vol.370 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 83
    • 77952300540 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
    • Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-50.
    • (2010) J Clin Oncol , vol.28 , pp. 2144-2150
    • Escudier, B.1    Bellmunt, J.2    Négrier, S.3
  • 84
    • 56749161699 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
    • Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8.
    • (2008) J Clin Oncol , vol.26 , pp. 5422-5428
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 85
    • 77952318310 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
    • Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43.
    • (2010) J Clin Oncol , vol.28 , pp. 2137-2143
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 86
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 87
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 88
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
    • Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.I.1    Escudier, B.2    Tomczak, P.3
  • 89
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 90
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
    • (2015) N Engl J Med , vol.373 , pp. 1803-1813
    • Motzer, R.J.1    Escudier, B.2    McDermott, D.F.3
  • 91
    • 84946552683 scopus 로고    scopus 로고
    • Cabozantinib versus everolimus in advanced renal-cell carcinoma
    • Choueiri TK, Escoudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23.
    • (2015) N Engl J Med , vol.373 , pp. 1814-1823
    • Choueiri, T.K.1    Escoudier, B.2    Powles, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.